MANGOCEUTICALS, INC. Files 8-K: Material Agreement, Equity Sales
Ticker: MGRX · Form: 8-K · Filed: Dec 6, 2024 · CIK: 1938046
| Field | Detail |
|---|---|
| Company | Mangoceuticals, INC. (MGRX) |
| Form Type | 8-K |
| Filed Date | Dec 6, 2024 |
| Risk Level | medium |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.0001, $40,000, $20,000, $25,000,000, $2.50 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, 8-k
TL;DR
MANGOCEUTICALS, INC. (MNGS) filed an 8-K on 12/2/24 covering a material agreement and equity sales.
AI Summary
On December 2, 2024, MANGOCEUTICALS, INC. filed an 8-K report detailing a material definitive agreement. The filing also covers unregistered sales of equity securities and includes financial statements and exhibits. The company is incorporated in Texas and its principal executive offices are located in Dallas.
Why It Matters
This 8-K filing signals significant corporate activity, including a new material agreement and equity transactions, which could impact the company's financial standing and future operations.
Risk Assessment
Risk Level: medium — The filing indicates material definitive agreements and unregistered equity sales, which can introduce financial and operational risks.
Key Numbers
- 001-41615 — SEC File Number (Identifies the company's filing with the SEC.)
- 87-3841292 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- MANGOCEUTICALS, INC. (company) — Registrant
- December 2, 2024 (date) — Date of Earliest Event Reported
- Texas (location) — State of Incorporation
- Dallas (location) — Principal Executive Offices City
- 15110 N. Dallas Parkway , Suite 600 (address) — Principal Executive Offices Street
FAQ
What is the nature of the material definitive agreement mentioned in the filing?
The filing does not specify the details of the material definitive agreement, only that one was entered into on or before December 2, 2024.
What type of equity securities were sold unregistered?
The filing indicates unregistered sales of equity securities but does not provide specific details on the type or amount of securities sold.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on December 2, 2024.
Where are MANGOCEUTICALS, INC.'s principal executive offices located?
MANGOCEUTICALS, INC.'s principal executive offices are located at 15110 N. Dallas Parkway, Suite 600, Dallas, Texas 75248.
What is the company's fiscal year end?
The company's fiscal year ends on December 31st.
Filing Stats: 1,524 words · 6 min read · ~5 pages · Grade level 13.9 · Accepted 2024-12-06 17:15:20
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 Par Value Per Share MGRX The Nasdaq
- $40,000 — ed upon issuance), and to pay Greentree $40,000 in cash, payable as follows: (a) $20,00
- $20,000 — 40,000 in cash, payable as follows: (a) $20,000 on or before December 31, 2024; and (b)
- $25,000,000 — e Purchaser committed to purchase up to $25,000,000 of the Company's common stock pursuant
- $2.50 — k pursuant to the terms of the ELOC for $2.50 per share for a total of $159,950, net
- $159,950 — ELOC for $2.50 per share for a total of $159,950, net of fees, discounts and expenses.
Filing Documents
- form8-k.htm (8-K) — 50KB
- ex10-1.htm (EX-10.1) — 87KB
- ex10-1_001.jpg (GRAPHIC) — 42KB
- ex10-1_002.jpg (GRAPHIC) — 12KB
- 0001493152-24-049133.txt ( ) — 401KB
- mgrx-20241202.xsd (EX-101.SCH) — 3KB
- mgrx-20241202_lab.xml (EX-101.LAB) — 33KB
- mgrx-20241202_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MANGOCEUTICALS, INC. Date: December 6, 2024 By: /s/ Jacob D. Cohen Jacob D. Cohen Chief Executive Officer